SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
TECH

BIO-TECHNE Corp (NASDAQ:TECH)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$72.67-$0.03 (-0.04%)
 
Market cap
$11.4B
Insider Score
Health Score
Analyst consensus
Listed since
Feb 9, 1989
Market Cap$11.42B+14.5%
Revenue (ttm)$1.23B+0.9%
Net Income$171.97M+120.5%
EPS$1.10+124.5%
Shares Out157.09M
PE Ratio66.06
Forward PE30.79
Dividend$0.40(0.55%)
Ex-Dividend DateNov 13, 2026
Volume3,663,187
Open$72.75
Previous Close$72.70
Day's Range$72.66 - $72.77
52-Week Range$43.20 - $72.88
Beta1.27
AnalystsHold
Price Target$71.67(-1.38%)
Earnings DateFeb 3, 2027

About TECH

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Address
614 McKinley Place N.E., Minneapolis, MN, 55413, US
Market Cap
11.42 billion
Employees
3,000
Industrial Classification
Biotechnology
Financial Health Score
Strong
From TECH’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-0.04%
5 Days
-0.12%
1 Month
+0.07%
6 Months
+50.74%
1 Year
+14.46%

$TECH stock is featured in our Congress Trading, and Insider Trades datasets.

→ All Stock Lists

Congress Trading

Recent trades of TECH by members of U.S. Congress

Julie JohnsonHouse / DSale$1.00K – $15.00KApr 1, 2025

Recently reported changes in TECH holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by TECH's directors and management

Net Shares Purchased by Insiders−1−102025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

TECH Estimated quarterly lobbying spending

Source: U.S. Senate LDA

TECH Revenue by Segment or Geography

$884.64MTotal
Revenues, net$299.71M33.88%
Product and Services$285.22M32.24%
Consumables$237.26M26.82%
Instruments$25.50M2.88%
Services$22.46M2.54%
Royalty revenues$14.49M1.64%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New TECH patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to TECH from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in TECH

VOOVanguard S&P 500 ETF$302.46M
VTIVanguard Morningstar Total Stock Market ETF$285.65M
VBVanguard Morningstar Small-Cap ETF$255.45M
RSPInvesco S&P 500 Equal Weight ETF$205.78M
SEQSequoia ETF$164.32M
IVViShares Core S&P 500 ETF$153.11M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from TECH’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
49
News & Sentiment
20% of score
72

News check: Q1 earnings beat and advancement of Merck KGaA merger deal provide concrete positive catalysts.

Recent Insider Activity

Buys
0
Sells
0
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

AINTFINQ DOLLAR NEUTRAL U.S. Large Cap AI-Managed Equity ETF52.20%
GNOMGlobal X - Genomics & Biotechnology ETF3.66%
MNANYLI Merger Arbitrage ETF3.46%
FBTFirst Trust NYSE Arca Biotechnology Index Fund3.28%
ARBAltShares Merger Arbitrage ETF2.49%
MRGRProShares - Merger ETF2.34%
GNMXCorgi ETF Trust I - Corgi Genomics & Precision Medicine ETF2.29%
RSPHInvesco S&P 500 Equal Weight Health Care ETF1.47%
RYHInvesco S&P 500 Equal Weight Health Care ETF1.47%
AEMCHarbor AlphaEdge Mid Cap Core ETF1.39%
AEMVHarbor AlphaEdge Mid Cap Value ETF1.15%
BBHVanEck Biotech ETF1.11%

Weight is the stock’s share of each fund’s holdings.